NCT06821906 Stereotactic Radiosurgery in the Treatment of Essential Tremor
| NCT ID | NCT06821906 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Maria Sklodowska-Curie National Research Institute of Oncology |
| Condition | Essential Tremor |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2030-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 42 participants in total. It began in 2024-12-16 with a primary completion date of 2030-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional study is to evaluate the effectiveness of treatment using stereotactic radiosurgery in the treatment of essential tremor in adult patients
Eligibility Criteria
Inclusion Criteria: * Essential tremor diagnosed, Parkinson's disease and other causes of tremor excluded. * Insufficient tremor control despite the use of available pharmacotherapy methods. * Disqualification from the Deeply Brain Stimualtion procedure/lack of consent to perform it on the side qualified for Stereotactic Radiosurgery * Consent to participate in a clinical trial. Exclusion Criteria: * Age under 50 * Pregnancy * Duration of the disease less than 5 years * Dementia, psychosis or other condition that prevents giving informed consent to participate in the study * Poor general condition, serious comorbidities * Structural changes in the basal ganglia or major atrophic changes * Previous radiotherapy to the brain covering the potential treatment area * Medical contraindications to magnetic resonance imaging
Contact & Investigator
Aleksandra Napieralska
PRINCIPAL INVESTIGATOR
Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch
Frequently Asked Questions
Who can join the NCT06821906 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Essential Tremor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06821906 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06821906 currently recruiting?
Yes, NCT06821906 is actively recruiting participants. Contact the research team at aleksandra.napieralska@gliwice.nio.gov.pl for enrollment information.
Where is the NCT06821906 trial being conducted?
This trial is being conducted at Gliwice, Poland.
Who is sponsoring the NCT06821906 clinical trial?
NCT06821906 is sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. The principal investigator is Aleksandra Napieralska at Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch. The trial plans to enroll 42 participants.